Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
or

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)
0.8161 +0.0153 (+1.91%) 16:00 ET [NASDAQ]
0.8121 x 8,800 0.8161 x 300
Realtime by (Cboe BZX)
0.8121 x 8,800 0.8161 x 300
Realtime - - (-) -
Quote Overview for Thu, Feb 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.7905
Day High
0.8287
Open 0.8100
Previous Close 0.8008 0.8008
Volume 360,516 360,516
Avg Vol 687,450 687,450
Stochastic %K 23.74% 23.74%
Weighted Alpha -67.57 -67.57
5-Day Change +0.0233 (+2.93%) +0.0233 (+2.93%)
52-Week Range 0.7500 - 5.8500 0.7500 - 5.8500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,670
  • Shares Outstanding, K 78,259
  • Annual Sales, $ 101,210 K
  • Annual Income, $ -570 K
  • EBIT $ 7 M
  • EBITDA $ 1 M
  • 60-Month Beta 1.01
  • Price/Sales 0.53
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 4.68
  • Earnings Per Share ttm 0.17
  • Most Recent Earnings $0.07 on 11/07/24
  • Next Earnings Date 03/10/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 350.33% ( +4.45%)
  • Historical Volatility 72.92%
  • IV Percentile 96%
  • IV Rank 46.27%
  • IV High 739.39% on 04/22/24
  • IV Low 15.34% on 09/19/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 19
  • Volume Avg (30-Day) 101
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 7,275
  • Open Int (30-Day) 6,608

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.20
  • Number of Estimates 5
  • High Estimate -0.01
  • Low Estimate -0.53
  • Prior Year 0.01
  • Growth Rate Est. (year over year) -2,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7500 +9.04%
on 02/12/25
Period Open: 0.8400
0.9800 -16.55%
on 02/06/25
-0.0222 (-2.64%)
since 01/17/25
3-Month
0.7500 +9.04%
on 02/12/25
Period Open: 0.8701
1.4200 -42.41%
on 12/04/24
-0.0523 (-6.01%)
since 11/20/24
52-Week
0.7500 +9.04%
on 02/12/25
Period Open: 1.4700
5.8500 -86.02%
on 05/01/24
-0.6522 (-44.37%)
since 02/20/24

Most Recent Stories

More News
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen (STK-001), its investigational candidate for treating Dravet syndrome, a severe and progressive...

CTMX : 0.8161 (+1.91%)
VYGR : 4.26 (-0.93%)
CSTL : 26.15 (-3.82%)
STOK : 8.74 (-6.02%)
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results

Shares of Mirum Pharmaceuticals MIRM were up 12.1% this week, driven by investor enthusiasm after the company announced encouraging preliminary sales numbers for the fourth quarter and full year 2024,...

CTMX : 0.8161 (+1.91%)
MIRM : 53.16 (+1.90%)
VYGR : 4.26 (-0.93%)
CSTL : 26.15 (-3.82%)
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)

Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for trofinetide to treat Rett syndrome in...

CTMX : 0.8161 (+1.91%)
VYGR : 4.26 (-0.93%)
CSTL : 26.15 (-3.82%)
ACAD : 20.29 (+3.15%)
ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals

Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for trofinetide to treat Rett syndrome in...

CTMX : 0.8161 (+1.91%)
VYGR : 4.26 (-0.93%)
CSTL : 26.15 (-3.82%)
ACAD : 20.29 (+3.15%)
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise

TG Therapeutics TGTX announced preliminary net product revenues for the fourth quarter and full-year 2024 for its marketed drug, Briumvi (ublituximab-xiiy), which exceeded the company’s initial expectations.TGTX...

TGTX : 30.94 (-0.23%)
CTMX : 0.8161 (+1.91%)
VYGR : 4.26 (-0.93%)
CSTL : 26.15 (-3.82%)
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down

SpringWorks Therapeutics SWTX announced preliminary net product revenues for fourth-quarter and full-year 2024 for its sole marketed drug, Ogsiveo (nirogacestat). The drug is approved for treating adult...

CTMX : 0.8161 (+1.91%)
VYGR : 4.26 (-0.93%)
CSTL : 26.15 (-3.82%)
SWTX : 59.93 (+7.54%)
Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy

Shares of Blueprint Medicines BPMC rallied 18.2% on Monday driven by investor enthusiasm following the company’s announcement of its 2025 corporate outlook and growth strategy, highlighting plans to...

CTMX : 0.8161 (+1.91%)
CSTL : 26.15 (-3.82%)
BPMC : 94.35 (+0.30%)
HALO : 57.44 (-0.57%)
PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

Shares of Pacira BioSciences PCRX gained 11.1% on Friday after the company shared better-than-expected preliminary fourth-quarter 2024 sales figures for its marketed products.Additionally, the company...

CTMX : 0.8161 (+1.91%)
CSTL : 26.15 (-3.82%)
PCRX : 25.74 (-1.15%)
HALO : 57.44 (-0.57%)
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data

Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results from a potentially groundbreaking type 1 diabetes (T1D) study of its experimental...

CTMX : 0.8161 (+1.91%)
CSTL : 26.15 (-3.82%)
SANA : 3.06 (-0.97%)
HALO : 57.44 (-0.57%)
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates

Vir Biotechnology, Inc. VIR announced encouraging initial data from a phase I study that evaluated its investigational pipeline candidates, VIR-5818 and VIR-5500, for the treatment of various solid tumors.While...

CTMX : 0.8161 (+1.91%)
PBYI : 2.92 (+1.39%)
CSTL : 26.15 (-3.82%)
VIR : 9.80 (-0.51%)

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

3rd Resistance Point 0.8655
2nd Resistance Point 0.8412
1st Resistance Point 0.8210
Last Price 0.8161
1st Support Level 0.7765
2nd Support Level 0.7522
3rd Support Level 0.7320

See More

52-Week High 5.8500
Fibonacci 61.8% 3.9018
Fibonacci 50% 3.3000
Fibonacci 38.2% 2.6982
Last Price 0.8161
52-Week Low 0.7500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements